Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice

home / peer-exchange / transforming-outcomes-in-hepatocellular-carcinoma-expert-insights-on-applying-evidence-to

Expert panelists review patient case studies and discuss key updates in the treatment landscape of advanced HCC from the 2023 ASCO Gastrointestinal Cancers Symposium and beyond.

Patients With Intermediate Stage HCC Unsuitable for TACE

EP. 1: Patients With Intermediate Stage HCC Unsuitable for TACE

February 20th 2023

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

EP. 2: Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

February 20th 2023

Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.

Patients With Intermediate Stage HCC Suitable for TACE

EP. 3: Patients With Intermediate Stage HCC Suitable for TACE

February 20th 2023

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

EP. 4: HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

February 20th 2023

Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.

Selecting the Appropriate Frontline Treatment in Advanced HCC

EP. 5: Selecting the Appropriate Frontline Treatment in Advanced HCC

March 6th 2023

Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.

Other Frontline Immunotherapy-based Combinations in Advanced HCC

EP. 6: Other Frontline Immunotherapy-based Combinations in Advanced HCC

March 6th 2023

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Patient Profile 2: Advanced HCC Treated with Lenvatinib

EP. 7: Patient Profile 2: Advanced HCC Treated with Lenvatinib

March 13th 2023

A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.

Real-World Evidence for Lenvatinib in Advanced HCC

EP. 8: Real-World Evidence for Lenvatinib in Advanced HCC

March 13th 2023

Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.